Kailai Medicine-B (02105.HK): Clinical trials of the new drug LAE103 have been approved by the United States Food and Drug Administration.

Wisdom Financial APP News, Lai Kai Pharmaceutical-B (02105.HK) has announced that the IND for LAE103 has been approved by the US FDA. The company is committed to providing this precise treatment for patients with metabolic diseases who need new treatment options.